If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan, individuals may only pay a 25% coinsurance.
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that doctors prescribe for adults with breathing difficulties. Costs can vary depending on many factors, including whether a person has insurance.
Individuals can have varying out-of-pocket costs with Medicare Part D prescription drug plans.
Private insurers provide Part D plans and can set different premiums and out-of-pocket costs, such as deductibles. However, plan providers cannot set Part D deductibles above $590 in 2025.
After an individual has paid $2,000 in out-of-pocket costs, including coinsurance contributions, Medicare will pay 100% of eligible expenses through the remaining calendar year.
All Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have lists of covered medications called formularies. To confirm whether Trelegy Ellipta is included in their formulary, a person can contact their plan provider directly and speak with a representative who will be able to advise of costs.
The Food and Drug Administration (FDA) approves Trelegy Ellipta for treating asthma and chronic obstructive pulmonary disease (COPD) in adults.
COPD mainly refers to
- chronic bronchitis
- emphysema
Over time, Trelegy Ellipta may help ease the symptoms of these conditions.
The FDA does not approve Trelegy Ellipta as a rescue inhaler to relieve sudden breathing difficulties. A doctor will prescribe a separate inhaler or similar medication for acute symptoms.
Medicare’s Extra Help program can help with the costs of prescription drugs.
People are automatically eligible for Extra Help if they have Medicaid, receive help with prescription drug costs from a Medicare savings program, or receive Supplemental Security Income (SSI) benefits.
